Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin

Gastroenterology. 2016 Jan;150(1):82-85.e4. doi: 10.1053/j.gastro.2015.09.011. Epub 2015 Sep 25.


Infection with hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients. Reduction of immunosuppression or treatment with ribavirin or pegylated interferon-α can result in viral clearance. However, safer and more effective treatment options are needed. Here, we show that sofosbuvir inhibits the replication of hepatitis E virus genotype 3 both in subgenomic replicon systems as well as a full-length infectious clone. Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect. Sofosbuvir may be considered as an add-on therapy to ribavirin for the treatment of chronic hepatitis E in immunocompromised patients.

Keywords: Antiviral; Chronic Hepatitis; Immunosuppression; Polymerase Inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacology*
  • Chronic Disease
  • Drug Synergism
  • Drug Therapy, Combination
  • Hepatitis E / drug therapy*
  • Hepatitis E virus / drug effects*
  • Hepatitis E virus / physiology
  • Humans
  • In Vitro Techniques
  • RNA, Viral / drug effects
  • RNA, Viral / physiology
  • Ribavirin / administration & dosage*
  • Ribavirin / pharmacology
  • Sofosbuvir / administration & dosage*
  • Sofosbuvir / pharmacology
  • Virus Replication / drug effects*


  • Antiviral Agents
  • RNA, Viral
  • Ribavirin
  • Sofosbuvir